Welcome to our dedicated page for Citius Oncology news (Ticker: CTOR), a resource for investors and traders seeking the latest updates and insights on Citius Oncology stock.
Citius Oncology, Inc. (Nasdaq: CTOR) generates a steady flow of news centered on its role as a platform for developing and commercializing novel targeted oncology therapies. Most recent company updates focus on LYMPHIR™ (denileukin diftitox-cxdl), an IL‑2 receptor-directed fusion protein approved by the FDA for adult patients with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma (CTCL) after at least one prior systemic therapy.
News coverage for CTOR frequently highlights key milestones in the commercial rollout of LYMPHIR. Company press releases describe the U.S. commercial launch of LYMPHIR, the transition from a pre‑revenue to a revenue-generating profile, and the completion of distribution agreements with the three leading U.S. pharmaceutical wholesalers, including a distribution services agreement with McKesson Corporation. These items explain how Citius Oncology aims to make LYMPHIR available to major medical centers, specialized hospitals, community oncology practices, and infusion centers.
Investors following CTOR can also expect updates on international access initiatives. Citius Oncology reports that it has secured access to LYMPHIR in 19 markets outside the United States via regional partners and Named Patient Programs, as well as exclusive distribution agreements in territories such as Turkey and certain Gulf Cooperation Council countries. Such announcements provide insight into the company’s global access strategy for CTCL patients.
Additional CTOR news items cover strategic financings, including registered direct offerings and private placements intended to support the LYMPHIR launch and general corporate purposes, as well as collaborations with technology partners like Verix to deploy AI-powered commercial optimization tools. Regulatory and corporate developments, such as SEC filings, proxy statements, and annual meeting results, also appear in the news flow. For a consolidated view of these earnings updates, commercialization milestones, financing transactions, and partnership announcements, the CTOR news page offers a single reference point that can be revisited as new disclosures are released.
Citius Pharmaceuticals (CTXR) and its oncology subsidiary Citius Oncology (CTOR) announced their participation in the upcoming Jefferies Global Healthcare Conference in New York City from June 3-5, 2025. Chairman and CEO Leonard Mazur will deliver a presentation on Thursday, June 5, 2025, at 3:10 pm ET.
The presentation will be available via live webcast and archived for later viewing on the company's website. Additionally, Mr. Mazur will engage in one-on-one meetings with institutional investors during the conference. Interested investors can arrange meetings through their Jefferies representatives.
Citius Pharmaceuticals (CTXR) reported its fiscal Q1 2025 results, highlighting preparations for the LYMPHIR commercial launch in H1 2025. The company secured a new J-code (J9161) for LYMPHIR, effective April 1, 2025, and reported promising preliminary results from an ongoing Phase I trial combining LYMPHIR with pembrolizumab.
Financial results showed cash and cash equivalents of $1.1 million as of December 31, 2024. The company reported a net loss of $10.3 million ($1.30 per share), compared to $9.2 million ($1.45 per share) in the prior year. R&D expenses decreased to $2.1 million from $2.6 million, while G&A expenses increased to $5.4 million from $3.7 million.
The company raised $6.5 million through offerings in late 2024 and early 2025, completed a 1-for-25 reverse stock split, and regained Nasdaq compliance.
Citius Oncology (NASDAQ: CTOR) reported its fiscal Q1 2025 financial results and business updates. The company has engaged Jefferies to explore strategic alternatives for maximizing shareholder value. Key developments include preparation for LYMPHIR™ launch in H1 2025, with inventory ready and a new permanent J-code (J9161) effective April 1, 2025.
Financial results show R&D expenses of $1.3M (vs $1.2M in Q1 2024), G&A expenses of $3.3M (vs $1.5M), and stock-based compensation of $1.8M (vs $1.9M). The company reported a net loss of $6.7M ($0.09 per share) compared to $4.7M ($0.07 per share) in Q1 2024.
Two investigator-initiated trials are exploring LYMPHIR's potential in combination therapies, with interim results presented at SITC Conference showing promise in combination with pembrolizumab for recurrent solid tumors.
Citius Pharmaceuticals and Citius Oncology announced that LYMPHIR™ (denileukin diftitox-cxdl) has received a permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) from the Centers for Medicare & Medicaid Services. The code will be effective April 1, 2025.
LYMPHIR is FDA-approved for treating adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The permanent J-code will help streamline billing and reimbursement processes for healthcare providers administering LYMPHIR, facilitating access for patients with commercial and government insurance coverage.
Citius Pharmaceuticals and its subsidiary Citius Oncology announced preparations for the commercial launch of LYMPHIR™ in the first half of 2025. LYMPHIR, approved in August 2024, is an immunotherapy treatment for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
The companies have made significant progress in key launch areas including: securing commercial supply agreements and producing first-year launch supply; implementing healthcare provider education programs; working on reimbursement pathways; submitting for a unique J-code; securing inclusion in NCCN guidelines; developing patient assistance programs; and building a specialized sales team.
Management is also exploring additional growth opportunities through international licensing partnerships and potential expanded indications for LYMPHIR, including its use as a combination immunotherapy.
Citius Oncology (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (Nasdaq: CTXR), has engaged Jefferies as its exclusive financial advisor to explore strategic alternatives for maximizing shareholder value. The company is considering various options including partnerships, joint ventures, mergers, acquisitions, and licensing transactions.
The announcement comes as Citius Oncology prepares to launch LYMPHIR™, their recently FDA-approved therapy for treating patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) who have undergone at least one prior systemic therapy.
The company has not established a specific timeline for this strategic review process and will only disclose developments if the Board of Directors approves a specific transaction or deems disclosure necessary. There is no guarantee that this process will result in any strategic transaction.
Citius Pharmaceuticals (CTXR) reported fiscal year 2024 results, highlighting key achievements including FDA approval of LYMPHIR™ for CTCL treatment and positive Phase 3 trial results for Mino-Lok®. The company reported cash and equivalents of $3.3 million as of September 30, 2024. Financial results show R&D expenses decreased to $11.9 million from $14.8 million, while G&A expenses increased to $18.2 million from $15.3 million. Net loss widened to $39.4 million ($5.97 per share) compared to $32.5 million ($5.57 per share) in 2023. The company completed merger of its oncology subsidiary to form Citius Oncology (CTOR) and plans LYMPHIR commercial launch in first half of 2025.
Citius Oncology (NASDAQ: CTOR) reported its fiscal year 2024 results and key developments. The company achieved FDA approval for LYMPHIR™, an immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), and began trading on Nasdaq under CTOR in August 2024. The company is preparing for LYMPHIR's commercial launch in H1 2025, including manufacturing inventory and initiating sales force recruitment.
Financial results showed R&D expenses of $4.9M (up from $4.2M in 2023), G&A expenses of $8.1M (up from $5.9M), and stock-based compensation of $7.5M (up from $2.0M). Net loss widened to $21.1M ($0.31 per share) compared to $12.7M ($0.19 per share) in 2023.
FAQ
What is the current stock price of Citius Oncology (CTOR)?
What is the market cap of Citius Oncology (CTOR)?
